Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > THRM is up over 30%

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jul 23, 2020 12:31pm

65 Views

Post# 31308431

RE:THRM is up over 30%

To bad were being held down with this underpriced dilutive pp all summer while the stock market keeps making gains

chris579457 wrote:
Unfortunately Vaxil has long way to accomplished positive results ,

It is entering animal pre-clinical studies ? , well we have other companies that entering 3^rd trials with millions to invest , this one is going nowhere